Bharat K. R. Chaganty

The University of Texas MD Anderson Cancer Center

Also affiliated with The University of Texas Health Science Center at Houston

Immunology and MicrobiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo”.

VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo

Blood Cancer Journal(2020)10.1038/s41408-020-00378-z

N/A

0DataRank · unranked

44 citations

Bharat K. R. Chaganty, Liang Lin, Lijie Xing, Boopathy Ramakrishnan, Kenneth Wen +18 more

Redirecting host preexisting influenza A virus immunity for cancer immunotherapy

Cancer Immunology Immunotherapy(2021)10.1007/s00262-021-03099-9

N/A

0DataRank · unranked

4 citations

Songbo Qiu, Lu Yang, Gabriel Lopez‐Berestein, Bülent Özpolat, Zhen Fan +1 more